Scientific Publications

Effects of oligonucleotide drug RBD8088 in mouse models of human glioblastoma

Kidney Specific Delivery of siRNAs Opens Options for Targeted Oligotherapeutic Treatment of CKD

FXI levels are related to endothelial function and endothelial activation biomarkers in patients with recent acute coronary syndrome

siRNA-mediated inhibition of PCSK9 by RBD7022: a first-in-human trial to evaluate safety, pharmacokinetics (PK) and pharmacodynamic (PD) effects alone and when added to statin treatment

High apo-CIII level correlates with poor lipid status, pro-inflammatory and fibrotic biomarker profile, and adverse cardiovascular outcome in patients with recent acute coronary syndrome

Inhibition of liver ApoC3 by GalNAc-conjugated siRNA RBD5044: First-in-human trial to evaluate the safety, pharmacokinetics (PK), and pharmacodynamic (PD) effects on atherogenic lipid profiles in healthy subjects